Integral Molecular said on Wednesday that it has entered into a second antibody discovery collaboration with Ono Pharmaceutical Co Ltd.

This second collaboration involves the discovery of candidate MAbs against an undisclosed target and leverages the power of Integral Molecular's MPS Antibody Discovery platform. It has used the MPS platform to discover antibody assets targeting other multipass membrane proteins, including GPCRs (CB1) and transporters (GLUT4).

Many of these MAbs are the first of their kind to be isolated, as complex membrane proteins have historically been extremely difficult targets for antibody discovery, added the company. Integral Molecular currently has therapeutic programmes focused on cancer, pain, immunity and metabolic disorders.

Headquartered in Osaka, Ono Pharmaceutical Co Ltd is an R&D pharmaceutical company committed to creating innovative medicines in specific fields, centered on oncology and diabetes.